Roche Diagnostics Operations, Inc.

Mochida Pharmaceutical Co., Ltd.

Lsi Medience Corporation

Boris Ivandic

Eberhard Spanuth

Kamon Shirakawa

Takeshi Matsuya

Yoshikazu Okamura

Shigeatsu Endo

Ralf Thomae

Okamura Yoshikazu

Endo Shigeatsu

Matsuya Takeshi

Shirakawa Kamon

Disclosed is a prediction method for the prognosis of sepsis comprising measuring an sCD14-ST level in a sample. sCD14-ST, to be measured in the present invention, is a marker superior to procalcitonin, known as a marker to predict the prognosis in sepsis patients.

Method for prediction of prognosis of sepsis

The present invention relates to a method of diagnosing acute pulmonary embolism (PE) in a subject including a) determining the amount of fibrin-fibrinogen degradation products, in particular D-dimer in a sample of the subject; b) determining the amount of a natriuretic peptide in a sample of the subject; c) determining the amount of a cardiac troponin in a sample of the subject; and d) comparing the amounts determined in steps a) to c) to reference amounts, thereby establishing the diagnosis. Included is also a method of deciding on a therapy of a subject diagnosed with PE and a method of monitoring the therapy.

D-dimer, troponin, and NT-proBNP for pulmonary embolism

Growing community of inventors

Munich, Germany

Boris Ivandic